Mometa Allergiespray Bei Heuschnupfen (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors. The activated receptor complex translocates to the nucleus and suppresses transcription of pro‑inflammatory cytokines, chemokines and other mediators, leading to decreased vascular permeability and edema in the nasal passages.

The exact dosing regimen is determined by the prescribing healthcare professional based on the severity of symptoms and patient characteristics. Typically, a few sprays per nostril once daily are prescribed, but the prescriber provides the specific instructions that should be followed precisely.

Safety in pregnancy and lactation has not been fully established. The product should only be used if the potential benefit justifies the potential risk, and this decision must be made by a qualified healthcare provider after evaluating the individual’s condition.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometa contains mometasone furoate, which has high topical potency and low systemic bioavailability, similar to other second‑generation nasal steroids such as fluticasone propionate. Compared with older agents, it often provides effective symptom control with a reduced risk of systemic side effects, but individual response may vary.

Store at room temperature, preferably below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

The spray is intended for intranasal use only. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the pump while breathing in gently through the nose. The recommended number of sprays per nostril is provided by the prescriber.

Although uncommon, serious adverse reactions can include nasal septal perforation, severe allergic reactions such as anaphylaxis, visual disturbances, and signs of adrenal suppression. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, severe headache, or systemic symptoms.

The spray should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, in patients with active untreated nasal infections, and in those for whom systemic corticosteroid therapy is contraindicated unless directed by a physician.